Ligliptin tablets and acarbose can be used in combination, the two have different mechanisms of action, for patients who are not well treated with a single hypoglycemic agent, they can be used in combination to control blood glucose, and blood glucose needs to be monitored when used to avoid hypoglycemia.
Ligliptin can control fasting and postprandial blood glucose by elevating the concentration of GLP-1 to increase insulin secretion and reduce blood glucose. Acarbose lowers blood sugar by inhibiting starch decomposition in the intestine and delaying glucose absorption, mainly controlling postprandial blood sugar. A small number of patients may experience angioedema, urticaria and diarrhea during the administration of Riglitazone, and Acarbose may have adverse reactions such as gastrointestinal flatulence and bowel sounds.
Diabetic patients should use the drug under the supervision of a doctor.